Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients

Bertrand, Dominique; Hanoy, M.; Edet, Stéphane; Lemée, Véronique; Hamzaoui, M.; Laurent, Charlotte; Lebourg, Ludivine; Étienne, Isabelle; Lemoine, Mathilde; Nezam, Dorian; Candon, Sophie; Plantier, Jean‐Christophe; Roy, Frank Le; Guerrot, Dominique

doi:10.1093/ckj/sfab100

Cited by 10 publications

(22 citation statements)

References 7 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After review, 105 articles were excluded owing to being a review article, case report, preprint, incorrect patient population, or duplicate cohort or having no outcomes of interest. A total of 83 studies 9 , 10 , 11 , 12 , 13 , 14 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ...…”

Section: Resultsmentioning

confidence: 99%

“…Among the studies analyzed, the weighted mean (range) seroconversion rate after 1 dose of mRNA vaccine was 10.4% (0%-37.9%) for antispike antibodies (18 studies 12 , 33 , 35 , 37 , 40 , 41 , 42 , 44 , 48 , 51 , 52 , 55 , 57 , 69 , 71 , 76 , 103 , 105 ) and 4.1% (0%-5.9%) for neutralizing antibodies (2 studies 12 , 69 ) ( Figure 2 ). The mean (range) antibody testing time was 25.5 (21-28) days after the first dose.…”

Section: Resultsmentioning

confidence: 99%

“…The weighted mean (range) total seroconversion rate after 2 doses of mRNA COVID-19 vaccines was 44.9% (0%-79.1%) for antispike antibodies (53 studies 10 , 11 , 12 , 13 , 14 , 32 , 35 , 36 , 38 , 40 , 41 , 42 , 43 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 69 , 70 , 71 , 74 , 79 , 80 , 82 , 84 , 86 , 88 , 91 , 92 , 93 , 94 , 95 , 97 , 102 , 103 , 105 ) and 22.6% (0%-47.5%) for neutralizing antibodies (8 studies 12 , 49 , 62 , <...>…”

Section: Resultsmentioning

confidence: 99%

“…Among studies reporting seroconversion rates after 2 doses of mRNA COVID-19 vaccines, we reviewed the rates of positive antibody response by types of the mRNA COVID-19 vaccines. The BNT162b2 vaccine had a weighted mean (range) seroconversion rate of 44% (range 0%-79.1%) for antispike antibodies (36 studies 11 , 13 , 35 , 40 , 41 , 42 , 43 , 45 , 46 , 47 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 57 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 69 , 70 , 80 , 84 , 86 , 88 , 91 , 92 , 93 , 102 , 105 ) and 15.3% (0%-35%) for neutralizing antibodies (5 studies 49 , 62 , 65 , 67 , 69 ). The mRNA-1273 vaccine demonstrated a weighted mean (range) seroconversion rate of 51.4% (29.9%-76.2%) for antispike antibodies (7 studies 10 , 12 , 32 , 48 , 79 , 103 , 105 ) and a mean of 26.9% for neutralizing antibodies (1 study 12 ).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant

et al. 2022

View full text Add to dashboard Cite

Key Points Question What are the humoral immune response rates and risk factors associated with diminished response after COVID-19 vaccination in recipients of solid organ transplant? Findings In this systematic review and meta-analysis of 29 studies and 11 713 recipients of solid organ transplant, seroconversion rates increased with progressively increased numbers of mRNA COVID-19 vaccine doses. Older age, recent transplantation, deceased donor status, active use of antimetabolites, and recent exposure to antithymocyte globulin or rituximab were risk factors associated with diminished humoral immune response after receiving 2 doses of mRNA vaccines. Meaning These findings suggest that more efforts are needed to modulate the risk factors associated with reduced humoral responses among recipients of solid organ transplant.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Seventeen studies described vaccine responses after two doses of SARS-COV-2-mRNA-vaccines, adverse events and disease after vaccination, which are summarized in Table 5a , Table 5b . [ [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] ]…”

Section: Resultsmentioning

confidence: 99%

COVID-19 and solid organ transplantation: Finding the right balance

Opsomer¹

2022

Transplantation Reviews

View full text Add to dashboard Cite

Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant

Seija

Rammauro

Santiago

et al. 2021

Clinical Kidney Journal

View full text Add to dashboard Cite

Background Antibody response against SARS-CoV-2 after mRNA or adenoviral vector based vaccines is weak in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines in KT. Here, we compare antibody response following vaccination with inactivated virus (Coronavacࣨ) and BNT162b2 mRNA. Methods A national multicenter cross-sectional study was conducted. The study group was composed of patients from all KT centers in Uruguay, vaccinated between May 1st-May 31st (Coronavacࣨ n = 245 and BNT162b2 n = 39). Control group was constituted by 82 healthy individuals. Participants had no prior confirmed COVID-19 test. Blood samples were collected between 30 and 40 days after second dose. Serum specific IgG antibodies against Receptor Binding Domain (RBD) of SARS-CoV-2 Spike protein were determined using COVID-19 IgG QUANT ELISA Kit. Results Only 29% of KT recipients showed seroconversion [36.5% BNT162b2, 27.8% inactivated virus, p = 0.248] in comparison to 100% in healthy control with either vaccine. Antibody levels against RBD were higher with BNT162b mRNA than with inactivated virus [173 (73–554) and 29 (11–70) BAU/mL, p < 0.034] in KT and 10 times lower than healthy control [inactivated virus: 308 (209–335) and BNT162b2: 2638 (2608–3808) BAU/mL, p < 0.034]. In multivariate analysis, variables associated with negative humoral response were age, triple immunosuppression, eGFR and time post-KT. Conclusion Seroconversion was low in KT patients after vaccination with both platforms. Antibody levels against SARS-CoV-2 were lower with inactivated virus than BNT162b mRNA. These findings support the need of strategies to improve immunogenicity in KT recipients after two doses of either vaccine.

show abstract

Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients

Cited by 10 publications

References 7 publications

Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant

Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant

COVID-19 and solid organ transplantation: Finding the right balance

Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant

Contact Info

Product

Resources

About